CHO-A04(CHO-A04) - 药物靶点：SSEA-4_在研适应症：局部晚期恶性实体瘤，肿瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名-

靶点

SSEA-4

作用方式

抑制剂

作用机制

SSEA-4抑制剂(SSEA-4抗原抑制剂)

治疗领域

肿瘤

在研适应症

局部晚期恶性实体瘤肿瘤

非在研适应症-

原研机构

台湾中央研究院

在研机构

台湾中央研究院

醣基生醫股份有限公司

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 CHO-A04 相关的临床试验

NCT07049458

/ Not yet recruiting临床1/2期

A Phase I/IIa, Open-Label, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHO-A04 in Subjects With Advanced Solid Tumors

The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment. The main questions it aims to answer are:
* Which dose of CHO-A04 shows the best anti-cancer ability?
* How will your body respond to CHO-A04 treatment?
* How long will CHO-A04 remain in your body?
There are two stages of investigation in this study:
* Phase I: to find the best anti-cancer dose of CHO-A04
* Phase IIa: to find the CHO-A04 anti-cancer ability in specific cancer types
In this study, each participant will be assigned to one of the CHO-A04 dose levels. Participants will have CHO-A04 infusion via blood vessel once every week for four weeks. The CHO-A04 treatment may continue based on participants' condition and CHO-A04 safety evaluations.

开始日期2025-12-01

申办/合作机构

醣基生醫股份有限公司

100 项与 CHO-A04 相关的临床结果

登录后查看更多信息

100 项与 CHO-A04 相关的转化医学

登录后查看更多信息

100 项与 CHO-A04 相关的专利（医药）

登录后查看更多信息

100 项与 CHO-A04 相关的药物交易

登录后查看更多信息